Ischemic Colitis and Amyloidosis: A Diagnostic Challenge

Authors

DOI:

https://doi.org/10.52787/agl.v52i3.231

Keywords:

Colitis, amiloidosis, ischemia, digestive hemorrhage

Abstract

Amyloidosis comprises a heterogeneous group of infiltrative diseases characterized by the extracellular deposition of insoluble protein fibrils. Any sector of the digestive tract can be affected directly or by infiltration of the autonomic nervous system. Descending and sigmoid colon are the most frequently involved sectors. Diagnosis is histological by Congo red staining. Ischemic colitis is the most frequent ischemic pathology of the gastrointestinal tract. Usually it is transient and reversible, with the left colon being habitually involved. Clinical manifestations are nonspecific and depend on the degree of ischemia and the affected sites. The gold standard for diagnosis is video colonoscopy. The topographic distribution of the lesions is usually territorial, segmental and patchy, depending on the occluded vasculature. The absence of pathognomonic findings for the diagnosis of ischemic colitis makes its determination difficult in the context of comorbidities such as amyloidosis. This disease can have the same clinical and endoscopic presentation. Ischemia not only constitutes one of the mechanisms of intestinal injury, but can also be a consequence of systemic involvement independently of colonic infiltration. The case of a 60-year-old patient with light chain-associated amyloidosis and colitis onset, who presented lower gastrointestinal bleeding and abdominal pain, is described and discussed. Due to the delayed diagnosis of colonic amyloidosis and the similarity with ischemic colitis, distinguishing between the two was a diagnostic challenge.

References

-1. Talar-Wojnarowska R, Jamiroziak K. Intestinal amyloidosis: Clinical manifestations and diagnostic challenge. Adv. Clin. Exp. Med. 2021;30(5):563-70.

-2. Ellen C. Ebert. Manifestaciones digestivas y hepáticas de las enfermedades sistémicas. En: M. Feldman, S. Friedman, J. Brandt. Sleisenger y Fordtran. Enfermedades digestivas y hepáticas. Fisiopatología, diagnóstico y tratamiento. 10a ed. Barcelona: Elsevier; 2018.p.579-616.

-3. Sattianayagam PT, Hawkins PN, Guillmore JD. Systemic amyloidosis and the gastrointestinal tract, Nat. Rev. Gastroenterol. Hepatol. 2009;6:608-17.

-4. Lado Lado FL, Ferreiro Regueiro MJ, Cabana González B, et al. Amiloidosis. Med. Integral. 2000;36(4):137-41.

-5. Maza I, Vlodavsky E, Eliakim RA. Rectal bleeding as a presenting symptom of AL amyloidosis and multiple myeloma. World J Gastrointest Endosc. 2010;2(1):44-6.

-6. Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis, Am J Gastroenterol. 2008;103:776-87.

-7. Syed U, Ching Companioni R, Alkhawam H, Walfish A. Amyloidosis of the gastrointestinal tract and the liver: clinical context, diagnosis and management. Eur. J. 2016;28:1109-21.

-8. Doulberis M, Panagopoulos P, Scherz S, Dellaporta E, Kouklakis G. Update on ischemic colitis: from etiopathology to treatment including patients of intensive care unit. Scand. J. Gastroenterol. 2016;51(8):893-902.

-9. Tadros M, Majumder S, Birk WJ. A review of ischemic colitis: is our clinical recognition and management adequate? Expert. Rev. Gastroenterol. Hepatol. 2013;7(7):605-13.

-10. Xu Y, Xiong L, Li Y, Jiang X, Xiong Z. Diagnostic methods and drug therapies in patients with ischemic colitis. Int. J. Colorectal Dis. 2020;36:47-56.

-11. Nikolic AL, Keck JO. Ischaemic colitis: uncertainty in diagnosis, pathophysiology and management. ANZ J. Surg. 2017;88(4):278-83.

-12. Theodoropoulou A, Koutroubakis IE. Ischemic colitis: clinical practice in diagnosis and treatment. World J. Gastroenterol. 2008;14(48):7302-8.

-13. García J, Rodríguez C. Amiloidosis cardiaca: estudio de caso y revisión bibliográfica. Rev. costarric. salud pública. 2019;28(1):74-82.

-14. Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. ASH. 2020;136(23):2620-27.

-15. Lim Y, Lee H, Jung S, Gwag HB, Kim DH, Kim SJ, et al. Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience. Korean J Intern Med. 2015;30(4):496-505.

-16. Iida T, Yamano H, Nakase H. Systemic amyloidosis with gastrointestinal involvement: Diagnosis from endoscopic and histological views. J. Gastroenterol. Hepatol. 2017;33:583-90.

-17. Montoro M, Brandt L.J, Santolaria S, Gomollon F, Sánchez Puértolas B, Vera J, et al. Clinical patterns and outcomes of ischaemic colitis: Results of the Working Group for the Study of Ischaemic Colitis in Spain (CIE study). Scand. 2011;46(2):236-46.

-18. Freudenthaler S, Hegenbart U, Schönland S, Behrens HM, Krüger S, Röcken C. Amyloid in biopsies of the gastrointestinal tract-a retrospective observational study on 542 patients. Virchows Arch. 2016;468:569-77.

-19. Yakupova E, Bobyleva L, Vikhlyantsev I, Bobylev AG. Congo Red and amyloids: history and relationship. Biosci Rep. 2019;39(1):1-4.

-20. Mitsudo S, Brandt, L. J. Pathology of Intestinal Ischemia. Surg. Clin. North Am. 1992;72(1):43-63.

-21. Sano S, Nishimori I, Miyao M, Kawamura K, Fukui Y, Taniki T, et al. Successful Use of Mesalamine in the Treatment of Chronic Segmental Lesion in a Case of Ischemic Colitis. J. Gastroenterol. Hepatol. 2003;18(7):882-3.

-22. Rysava R. AL amyloidosis: advances in diagnostics and treatment. Nephrol Dial Transplant. 2019;34(9):1460-6.

Published

2022-09-29

How to Cite

Benitez, F., & Pontet, Y. (2022). Ischemic Colitis and Amyloidosis: A Diagnostic Challenge. Acta Gastroenterológica Latinoamericana, 52(3), 395–401. https://doi.org/10.52787/agl.v52i3.231